Today's Research Reports on Trending Tickers: CRISPR Therapeutics and Editas Medicine
NEW YORK, NY / ACCESSWIRE / July 25, 2018 / U.S. markets finished moderately higher on Tuesday, fueled by strong corporate earnings as Google quarterly results topped expectations. The Dow Jones Industrial Average gained 0.79 percent to close at 25,241.94, w5hile the S&P 500 Index was up 0.48 percent to close at 2,820.40. The Nasdaq Composite Index decreased 0.01 percent to close at 7,840.77.
''This quarter is shaping up to be another barnburner of a quarter. We're seeing a very large percentage of companies beating expectations and we don’t think we've seen a peak yet,'' said portfolio manager at TrimTabs Asset Management, Janet Johnston.
RDI Initiates Coverage on:
CRISPR Therapeutics AG
https://rdinvesting.com/news/?ticker=CRSP
Editas Medicine, Inc.
https://rdinvesting.com/news/?ticker=EDIT
CRISPR Therapeutics' stock moved 9.53% lower Tuesday, to close the day at $51.81. The stock recorded a trading volume of 2,847,031 shares, which was above its three months average volume of 1,524,906 shares. In the last year, CRISPR Therapeutics' shares have traded in a range of 16.16 - 73.90. The share price has gained 220.61% from its 52 week low. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $62.07 is above its 200-day moving average of $51.18. Shares of CRISPR Therapeutics have fallen roughly 17.47 percent in the past month and are up 120.66 percent year-to-date.
Access RDI's CRISPR Therapeutics AG Research Report at:
https://rdinvesting.com/news/?ticker=CRSP
On Tuesday, shares of Editas Medicine recorded a trading volume of 1,899,083 shares, which was above the three months average volume of 992,768 shares. The stock ended the day 8.23% lower at $32.46. The share price has fallen 27.9% from its 52 week high with a 52 week trading range of 15.28 - 45.02. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $37.37 is above its 200-day moving average of $35.70. Shares of Editas Medicine have fallen roughly 17.55 percent in the past month and are up 5.63 percent year-to-date.
Access RDI's Editas Medicine, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=EDIT
Our Actionable Research on CRISPR Therapeutics AG (NYSE: CRSP) and Editas Medicine, Inc. (NASDAQ : EDIT) can be downloaded free of charge at Research Driven Investing.
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
CONTACT
For any questions, inquiries, or comments reach out to us directly at:
Address:
Email:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: RDInvesting.com
